Published in Women's Health Weekly, June 15th, 1998
The results, presented by Allen Mangel, MD, clinical research director, Glaxo Wellcome Inc., during the Digestive Disease Week (DDW) conference in New Orleans, Louisiana, showed that the proportion of female patients who reported adequate relief of IBS-related pain and discomfort was significantly greater with alosetron (1 and 2 mg BID) than the proportion of patients reporting adequate relief with placebo. Female patients taking alosetron also reported improved stool...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.